Organon & Co. (OGN)

$21.80 0.28 (1.30%)

19:00 EDT OGN Stock Quote Delayed 30 Minutes

OGN Stock Earnings: Organon Beats EPS, Beats Revenue for Q1 2024

By InvestorPlace Earnings May 2, 2024

OGN stock results show that Organon beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024

3 Healthcare Stocks With the Potential to Triple Your Investment by 2026

Turn $500 into a Fortune: 3 Top Stock Picks for March’s Million-Dollar Rally

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 1.67M

Day's Range $21.43 - $21.98

52-Week Range $10.84 - $24.08

Dividend & Yield $1.12 (5.14%)

OGN Stock Predictions, Articles, and Organon & Co. News

From InvestorPlace
From the Web

Under the Radar: 3 Overlooked Stocks Ready to Dominate the Market

By Yiannis Zourmpanos, InvestorPlace Contributor Feb 26, 2024

Explore growth strategies of overlooked stocks with strong fundamentals in strategic investments and market expansion.

3 S&P 500 Stocks to Own for the Next 50 Years

By Will Ashworth, InvestorPlace Contributor Jul 4, 2023

These three S&P 500 companies all buy and hold stocks for the next 50 years or more because they operate in attractive industries.

7 Stocks That Are Long Overdue for a Relief Rally

By Chris Lau, InvestorPlace Contributor May 18, 2023

Here are seven stocks with the catalysts and fundamentals to support a sustained relief rally in this environment.

7 Growth Stocks That Are Trading at a Bargain Price

By Chris Markoch, InvestorPlace Contributor Apr 2, 2023

It’s too early to say the market has turned the corner, but some analysts suggest that equities could be at the beginning of a bull…

3 Recent Spin-Off Stocks Worth A Spot in Your Portfolio

By Tezcan Gecgil, InvestorPlace Contributor Nov 19, 2021

Spin-off stocks can be lucrative for shareholders in both legacy businesses and recently created public companies. Here are three to know.

Stay Away From Low-Growth Organon

By Larry Ramer, InvestorPlace Contributor Jul 8, 2021

Organon's low growth, lack of strong catalysts and likely average future dividend combine to make OGN stock unattractive.

Don’t Miss the Opportunity Presented by Organon Stock

By David Moadel, InvestorPlace Contributor Jun 23, 2021

If a company's spun off from a pharmaceutical giant, you'd think the buzz about it would be deafening. Yet OGN stock remains an underappreciated gem.

Motivation Really Matters When It Comes to Organon

By Josh Enomoto, InvestorPlace Contributor Jun 17, 2021

Although spinoffs of well-known organizations have been known to outperform, you’ll want to examine OGN stock carefully.

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

By Sarah Smith, Editor-in-Chief, InvestorPlace.com Jun 3, 2021

So what did the stock market do today? Investors turned to new meme stocks like XERS and watched the OGN stock spinoff launch.

Merck Spinoff Organon Will Do Well Over Time

By Mark R. Hake, CFA Jun 2, 2021

The Merck spinoff Organon will likely do quite well. OGN stock is likely to be worth $52.77, or 48% above the when-issued price right now.

Organon stock nears five-month high after Q4 beat (NYSE:OGN)

From Seeking Alpha Feb 15, 2024

Organon (OGN) stock spikes as the women's healthcare company beats Q4 2023 expectations and offers in-line guidance for 2024. Read more here.

Organon stock on the rise ahead of Q4 earnings (NYSE:OGN)

From Seeking Alpha Feb 14, 2024

Organon (OGN) is gaining positive ciew on Wall Street, and its share price is rising ahead of its Q4 2023 results on Thursday, before the opening bell. Read more here.

Organon & Co. set to break its six-day losing streak (NYSE:OGN)

From Seeking Alpha Jan 22, 2024

SA contributor, Gen Alpha said, the company has faced challenges in its women's health segment but expects a turnaround in its top-selling drug and growth in th

Organon says Xaciato now available nationwide (NYSE:OGN)

From Seeking Alpha Jan 10, 2024

Organon (OGN) said that Xaciato, a formulation of clindamycin phosphate, is now available nationwide for the treatment of bacterial vaginosis in females aged 12

Is This Healthcare Stock's 10% Yield a Steal of a Deal or Too Good to Be True?

From The Motley Fool Nov 21, 2023

High-yielding stocks may be tantalizing, but they often come with risks.

Need an Extra $4,000 in Dividends Each Year? Invest $68,000 in These 3 Stocks.

From The Motley Fool Jul 21, 2023

These stocks can significantly bolster your income.

ADVERTISEMENT